Akari Therapeutics Expands ADC Pipeline with CEACAM5-Targeting AKTX-102
Event summary
- Akari Therapeutics filed a U.S. provisional patent (No. 63/958,508) for AKTX-102, an ADC targeting CEACAM5, a challenging oncology target expressed in 80–90% of gastrointestinal cancers.
- AKTX-102 combines a novel CEACAM5-targeting antibody with Akari’s proprietary PH1 spliceosome-modulating payload, designed to enhance tumor cell killing and immune activation.
- The company’s patent estate now includes multiple filings covering payload biology, ADC architecture, and combination strategies, creating a layered IP moat.
- Akari aims to submit AKTX-101 for regulatory review by late 2026/early 2027, with Phase 1 trials expected to begin shortly after.
The big picture
Akari Therapeutics is strengthening its position in the ADC space by expanding its pipeline with AKTX-102, a novel therapy targeting CEACAM5, a historically difficult oncology target. The company’s growing patent estate and focus on RNA-splicing payloads differentiate it in a competitive market, with key milestones in 2026 set to validate its strategy. The success of AKTX-101 and AKTX-102 could solidify Akari’s role as a leader in next-generation cancer therapies.
What we're watching
- Clinical Execution
- Whether Akari can successfully advance AKTX-101 through regulatory interactions and into Phase 1 trials by late 2026/early 2027.
- IP Strategy
- The pace at which Akari expands its patent portfolio to protect its novel ADC constructs and payload innovations.
- Market Differentiation
- How AKTX-102’s unique approach to targeting CEACAM5 positions Akari against competitors in the ADC space.
Related topics